Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials.
Kangning Wang, Jialei Hu, Huagen Chen et al.
✦ AI-curated · Sources linked
In 30 seconds
Two single-center, randomized, double-blind Phase 1 and Phase 2 trials assessed the safety and immunogenicity of a 24-valent pneumococcal conjugate vaccine (PCV24) in healthy Chinese adults aged 18 years or older. Phase 1 compared PCV24 doses with PPSV23 or placebo; Phase 2 compared three PCV24 formulations with PPSV23. Adverse reactions were mainly grade 1–2, and no vaccine-related serious adverse events occurred over 6 months. In Phase 2, the high-dose PCV24 group met non-inferiority criteria versus PPSV23 for IgG seroconversion across all 24 serotypes.
Key findings
- Adverse reactions within 30 days were primarily grade 1–2; rare grade 3 events were limited to days 0–7.
- No vaccine-related serious adverse events occurred over 6 months.
- High-dose PCV24 met non-inferiority criteria versus PPSV23 for IgG seroconversion across all 24 serotypes in participants aged ≥18 years.
Why it matters
A conjugate vaccine covering 24 pneumococcal serotypes could broaden vaccine coverage. These early-phase trials provide safety and immunogenicity evidence in Chinese adults, while the comparison with PPSV23 offers a benchmark for antibody responses. The findings are relevant to vaccine development, but do not establish clinical protection against pneumococcal disease.
What to keep in mind
The trials were single-center and assessed safety and immunogenicity rather than clinical efficacy; the abstract calls for further efficacy studies in larger populations.